ST. LOUIS, Nov. 24 /PRNewswire/ -- A study released recently in the British Journal of Urology detailed the results from biopsies of 140 men who received care at Washington University in St. Louis, Duke University, and the University of Michigan. The study, titled “Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer,” found that TargetScan(R) template guided biopsy technology potentially produces a higher cancer detection rate and more accurate assessment of grade.
The TargetScan system combines 3-D image acquisition with a stationary probe, which helps physicians plan and execute targeted prostate biopsies through accurate needle placement within a template, which in turn, can provide confidence in identifying locations of significant cancer in the prostate.
“As physicians we are challenged to provide accurate diagnosis and define the true extent of the disease so we don’t over or underestimate the significance of the cancer,” said Dr. Gerald Andriole, Professor and Chief of Urology at Washington University in St Louis School of Medicine, a member of the multi-center team that conducted the evaluation of TargetScan. The study’s lead author, Dr. Adam Kibel, also from Washington University, agrees. “This technology allows physicians to accurately biopsy the prostate since the location of each biopsy is calculated on the basis of the prostate’s size and shape. This may allow us to more accurately find and define the disease. This may allow better monitoring of patients on active surveillance. Importantly, since the location of each biopsy site is recorded, re-biopsy or treatments can be performed with more precision.”
TargetScan Touch(TM) is the most current system based on the TargetScan technology platform. TargetScan Touch was unveiled recently at the 2008 American Society for Therapeutic Radiology and Oncology annual meeting, and has been tested at several of the nation’s leading medical centers.
TargetScan technology is developed by Envisioneering Medical Technologies in St. Louis, under the guidance of physicians at Washington University in St. Louis. “Traditional hand-manipulated devices allow the prostate gland to shift, which impedes accurate biopsy and placement accuracy. By stabilizing the prostate, physicians can now detect cancer with greater confidence,” said Robert Mills, president, Envisioneering Medical Technologies.
About Envisioneering Medical Technologies
Envisioneering Medical Technologies, based in St. Louis, Mo., is dedicated to creating the standard for prostate cancer care by developing technology for improving prostate cancer diagnosis and treatment precision and effectively managing patients throughout the continuum of care. For more information please visit http://www.envisioneeringmedical.com.
KM-0022 A
CONTACT: Cheri Winchester, cwinchester@commongroundpr.com, or Nina Kult,
nkult@commongroundpr.com, both for Envisioneering Medical Technologies,
+1-636-530-1235
Web site: http://www.envisioneeringmedical.com/
